pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,159 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1172Endpoints885BioPharma Dive340BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7564Rare Disease1864Cardiology1738Immunology1478Hematology1318Vaccines1197Pulmonology
  • VC Julie Grant argues U.S. should not restrict biotech investments in China
    Julie Grant, a venture capitalist, told STAT+ that she opposes any U.S. effort to limit biotech investments in China. She says the biotech sector has become increasingly interdependent over decade…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Triveni Bio secures $65M Series C as second eczema candidate enters clinical trials
    Triveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs. The round was co‑led by Ascenta Capital and Janus Henderson Investors, with parti…
    Endpoints · 2mo agoDealPositive↗ source
← prev
page 81 of 127
next →
fda recalls67
fda medwatch60
fda press38
1147
Psychiatry & CNS866
Ophthalmology494
Pain478
Endocrinology & Metabolism471
Infectious Disease444
  • Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipeline
    Vedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…
    Endpoints · 2mo agoDealPositive↗ source
  • FTC and Four State Attorneys General Sue Transgender Health Group Over Alleged Misleading Claims
    The Federal Trade Commission, together with attorneys general from Alaska, Iowa, Nebraska and Texas, filed a lawsuit on Wednesday in a Texas federal court against the World Professional Association…
    STAT · 2mo agoRegulatoryNegative↗ source
  • NIH Diversity Programs Found to Double Undergraduate PhD Odds in 20-Year Study
    A 20‑year study published in Science Advances reports that two NIH‑funded diversity initiatives, the Research Initiative for Scientific Enhancement (RISE) and Minority Access to Research Careers (M…
    STAT · 2mo agoNeutral↗ source
  • Trump administration moves special-education oversight to Health and Human Services
    The Trump administration announced that responsibility for special education will be transferred from the Department of Education to the Department of Health and Human Services. This change is part…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Advocacy groups urge FDA to revoke approval of antibiotics used for disease prevention in livestock
    More than 60 organizations have filed a petition with the FDA asking the agency to withdraw its approval for the use of antibiotics in food‑producing animals for disease prevention and growth promo…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Abridge’s Patient-Centered Claim Scrutinized in STAT AI Prognosis
    Brittany Trang, a health‑tech reporter, wrote a piece for STAT’s AI Prognosis newsletter that takes a close look at Abridge’s assertion that its ambient scribe platform is "patient‑centered." The…
    STAT · 2mo agoNegative↗ source
  • Oncologists Find Deep Joy in Delivering Hope to Patients and Families
    Khushali Jhaveri, a lymphoma specialist at Indiana University, shares a personal view of what makes oncology rewarding. She recounts a recent encounter with a patient who had endured multiple trans…
    STAT · 2mo agoPositive↗ source
  • STAT decides to keep “health care” as two words despite AP style change
    STAT’s editorial team faced a dilemma after the Associated Press Stylebook announced that “healthcare” will now be written as a single word. The change, revealed at the AP Editors Conference, spark…
    STAT · 2mo agoNeutral↗ source
  • Murder suspect plans psychiatric defense in killing of UnitedHealthcare CEO
    Luigi Mangione has told the court he will rely on a psychiatric defense, arguing that he was suffering from extreme emotional disturbance when he shot UnitedHealthcare chief Brian Thompson. If a j…
    STAT · 2mo agoNegative↗ source
  • Neumora ends development of navacaprant after failed Phase 3 depression trials; EnGene cuts half its workforce
    Neumora Therapeutics announced it will discontinue its kappa opioid receptor antagonist navacaprant after the drug missed its primary endpoints in two Phase 3 studies for major depressive disorder.…
    BioPharma Dive · 2mo agoNegative readoutNegative↗ source
  • Eli Lilly to acquire non-opioid pain drug developer 4E Therapeutics, adding MNK inhibitor pipeline
    Eli Lilly announced it will purchase 4E Therapeutics, a biotech focused on non‑opioid pain treatments. The acquisition gives Lilly access to 4E’s experimental pipeline, including MNK inhibitors su…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Edgewise Therapeutics' experimental heart drug meets Phase 2 endpoints in cardiomyopathy trial
    Edgewise Therapeutics reported that its oral candidate EDG-7500 achieved the predefined goals of a Phase 2 study in both obstructive and non‑obstructive hypertrophic cardiomyopathy. The trial demo…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Medicare to Cover Obesity Drugs for Adults 65+ Starting Next Month
    Medicare will begin covering prescription weight‑loss medications for beneficiaries aged 65 and older starting next month, marking the first time the program includes such drugs. The coverage is p…
    STAT · 2mo agoRegulatoryPositive↗ source
  • FDA gives modest backing to Moderna’s flu vaccine, noting efficacy questions but no major concerns
    The FDA released briefing documents ahead of an advisory committee meeting on Moderna’s seasonal influenza vaccine. The agency’s assessment was described as tepid, highlighting some questions abou…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • FDA approves Colorado plan to import lower-cost drugs from Canada
    The U.S. Food and Drug Administration issued a letter confirming that Colorado may move forward with a pilot program to bring prescription medicines from Canada. The proposal aims to lower drug co…
    Endpoints · 2mo agoRegulatoryPositive↗ source
  • Biotech Converts Failed Trial Data into AI Model
    A biotech startup recently faced a setback when a clinical trial did not achieve its primary goals. Rather than discarding the results, the company chose to analyze the data for new insights. The…
    STAT · 2mo agoPositive↗ source
  • Express Scripts and PCMA file lawsuits to block Tennessee FAIR Rx Act targeting PBM-owned pharmacies
    Express Scripts, a Cigna subsidiary, and the Pharmaceutical Care Management Association have filed separate lawsuits in federal court in Tennessee. The suits challenge the FAIR Rx Act, a law passe…
    BioPharma Dive · 2mo agoRegulatoryNeutral↗ source
  • FDA staff raise concerns over data for Moderna’s mFlusiva flu vaccine ahead of advisory panel
    FDA staff have examined the evidence for Moderna's mFlusiva, an mRNA flu vaccine, and highlighted shortcomings in the data submitted to the agency. The Food and Drug Administration will convene an…
    BioPharma Dive · 2mo agoRegulatoryNegative↗ source
  • Edgewise Therapeutics moves heart disease drug into Phase 3 after updated Phase 2 data
    Edgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial. The decision follows an updated a…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Eli Lilly acquires another pain biotech, its 11th deal this year, as FDA eyes decision on once‑weekly PrEP pill
    Eli Lilly announced the purchase of an Austin, Texas‑based pain biotechnology company, marking the 11th acquisition the Indianapolis‑based firm has completed in 2026. The deal expands Lilly's portf…
    Endpoints · 2mo agoDealNeutral↗ source
  • Verge Labs launches AI tool to boost patient enrollment and trial efficiency; Moderna appoints new chief commercial officer
    Verge Labs announced a new artificial‑intelligence model designed to identify patients most likely to respond to a therapy, aiming to reduce dropout rates and increase the statistical power of clin…
    STAT · 2mo agoPositive↗ source
  • Verge Labs launches AI tool to improve neurology trial patient selection after ALS setback
    Verge Labs, formerly known as Verge Genomics, announced a new artificial intelligence model designed to address patient stratification challenges in neurology clinical trials. The company says the…
    STAT · 2mo agoPositive↗ source
  • Congress urged to swiftly reauthorize Pandemic and All-Hazards Preparedness Act
    Former assistant secretary for preparedness Craig Vanderwagen and former Senate staffer Jennifer Alton argue that the Pandemic and All-Hazards Preparedness Act needs prompt reauthorization. They no…
    STAT · 2mo agoRegulatoryNeutral↗ source